Home > Focus Areas > Type 2 Diabetes Connect > Post
  • Saved

8h
Cardiorenal-protective therapy in type 2 diabetes: comparative outcomes evidence and individualized treatment beyond glycemic control

Type 2 diabetes management has evolved, with cardiorenal outcome data repositioning SGLT2 inhibitors and GLP-1 receptor agonists as first-line options for patients with established cardiovascular disease, heart failure, or chronic kidney disease, independent of glycemic targets.

A comparative real-world cohort of 364,714 patients with type 2 diabetes at moderate cardiovascular risk demonstrated that SGLT2 inhibitors and GLP-1 receptor agonists significantly reduced kidney composite outcomes versus DPP-4 inhibitors and sulfonylureas, with SGLT2 inhibitors outperforming GLP-1 receptor agonists (HR 0.81). These findings support early cardiorenal-protective therapy initiation regardless of baseline glycemic control. Effective individualization, balancing cardiovascular, renal, and metabolic comorbidities with patient preferences, tolerability, and cost, remains central to optimized diabetes care.

Endocrinologists, diabetologists, primary care physicians, and cardiologists managing type 2 diabetes will benefit from peer discussion of cardiorenal-protective therapy sequencing, treat-beyond-glucose frameworks, individualized HbA1c target setting, and adherence strategies.

How do cardiorenal risk factors, including cardiovascular disease, heart failure, and chronic kidney disease, influence your initial choice of glucose-lowering agent, and when do you prioritize organ protection over glycemic management alone? What practical strategies do you employ to overcome therapeutic inertia in escalating to SGLT2 inhibitors or GLP-1 receptor agonists in patients who have not met individualized targets on existing regimens?

  • 8h
    Tend to chose GLP-1 over SGLT2 for patients were weight loss is important for them and reducing BMI would help other chronic medical conditions like OA in knees as well as improve their mental health. Stress importance of dietary changes and physical activity for additional benefits and also search for other causes like hypercortisolism.
  • Yesterday
    These medications are now standard of care and so I have been utilizing both categories much sooner than previously. It would be easier if insurance did not require quite so many PAs for these meds although it is a little better now that Farxiga is generically available.
  • 3d
    I initiate these medications early on in the treatment of diabetes with my patients, regardless of glucose status. I usually choose GLP-1s first, however if someone has CKD then I will add SGLT2.
  • 3d
    I try to initiate these medications early when patients are establishing with me, or when newly diagnosed with diabetes in my care, to reduce hesitancy in therapy uptake. I discuss how these medications have overlapping benefit for diabetes and their other diagnoses, and strongly encourage transitioning patients to these, especially when they are on inferior oral options or insulin. Patients often are eager to discontinue insulin therapy, so this helps overcome hesitancy as well.
  • 5d
    it is the gold standard now and is in the updated literature for treatment for patients with dm and heart disease and are usually well tolerated but adjustments can be made if significant side effects are experienced, also these medications should be used regardless of glucose status although this is an endpoint that is important but should not be the goal of treatment with these therapies
  • 5d
    the current changes in diabetic care with new medications that have entered the market and have become the standard of care
  • 1w
    In patients with type 2 diabetes and cardiorenal comorbidities—established atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk, heart failure (HF), or chronic kidney disease (CKD) an SGLT2 inhibitor and/or a GLP-1 receptor agonist with demonstrated cardiovascular or kidney benefit should be prioritized independent of baseline A1C, independent of metformin use, and independent of whether the glycemic target has already been met.
    This reflects a fundamental shift from a glucose-centric to an organ-protection–centric paradigm: the cardiorenal benefits in the outcome trials were largely independent of A1C reduction, so these agents are used for risk reduction rather than solely for glycemic lowering.
  • 2w
    I choose SGLT2 inhibitors and Ozempic early on for patients with CKD or CHF with Type 2 diabetes. Not only I improve or stabilize the comorbid conditions , I get substantial improvement in A1c especially with Ozempic..
  • 2w
    Anyone with hyperglycemia and significant CV risk factors should be on either an SGLT-2 or GLP-1 medication. Making patients and physicians aware of the end goals is critical to escalation of therapy
  • 2w
    SGLT2- Inhbitors have changed the landscape of their use beyond diabetes in Cardiorenal Protection some time ago and every diabetic pt needs to be on it and question needs to be addressed why this diabetic pt can not be prescribed it even if they have good glycemic control Similarly GLP-1 agnoist must be prescribed for all obese diabetic pts for the same CV attributed in addition for Glycemic and Weight management
  • 2w
    SGLT 2 inhibitors are chosen now as first line in patients with any comorbid conditions for their protective effects followed by GLP 1 agonists by protection takes precedence especially in more sick patients over glucose control.I rarely use sulfonylurea anymore.
  • 2w
    So we are to the point where GLP1 and SGLT are fist line for diabetes. Initial choices based on risk factors like kidney disease albuminuria, CAD etc.
    I tend to think the all patients are candidates for both GLP1 and SGLT based on prevention data alone.
  • 3w
    In patients with type 2 diabetes who have cardiovascular disease, heart failure, or chronic kidney disease, I prioritize medications that protect the heart and kidneys—especially SGLT2 inhibitors or GLP-1 receptor agonists—even if blood sugar is reasonably controlled. I choose the therapy based on the patient’s overall health, kidney function, cardiovascular risk, preferences, side effects, and cost, rather than HbA1c alone. To reduce therapeutic inertia, I regularly reassess treatment, educate patients about the long-term benefits beyond glucose lowering, address cost and adherence barriers, and escalate therapy promptly when individualized goals are not being met.

Show More Comments